Bonney Stephanie, Hughes Kelly, Eckle Tobias
Department of Anesthesiology, University of Colorado Denver, 12700 E 19th Avenue, Mailstop B112, RC 2, Room 7121, Aurora, CO 80045.
Curr Pharm Des. 2014;20(36):5690-5. doi: 10.2174/1381612820666140204102524.
Brief periods of cardiac ischemia and reperfusion exert a protective effect against subsequent longer ischemic periods, a phenomenon coined ischemic preconditioning. Similarly, repeated brief episodes of coronary occlusion and reperfusion at the onset of reperfusion, called post-conditioning, dramatically reduce infarct sizes. Interestingly, both effects can be achieved by the administration of any volatile anesthetic. In fact, cardio-protection by volatile anesthetics is an older phenomenon than ischemic pre- or post-conditioning. Although the mechanism through which anesthetics can mimic ischemic pre- or post-conditioning is still unknown, adenosine generation and signaling are the most redundant triggers in ischemic pre- or post-conditioning. In fact, adenosine signaling has been implicated in isoflurane-mediated cardioprotection. Adenosine acts via four receptors designated as A1, A2a, A2b, and A3. Cardioprotection has been associated with all subtypes, although the role of each remains controversial. Much of the controversy stems from the abundance of receptor agonists and antagonists that are, in fact, capable of interacting with multiple receptor subtypes. Recently, more specific receptor agonists and new genetic animal models have become available paving way towards new discoveries. As such, the adenosine A2b receptor was shown to be the only one of the adenosine receptors whose cardiac expression is induced by ischemia in both mice and humans and whose function is implicated in ischemic pre- or post-conditioning. In the current review, we will focus on adenosine signaling in the context of anesthetic cardioprotection and will highlight new discoveries, which could lead to new therapeutic concepts to treat myocardial ischemia using anesthetic preconditioning.
短暂的心脏缺血和再灌注对随后更长时间的缺血期具有保护作用,这一现象被称为缺血预处理。同样,在再灌注开始时反复短暂的冠状动脉闭塞和再灌注,即后处理,可显著减小梗死面积。有趣的是,这两种效应均可通过给予任何挥发性麻醉剂来实现。事实上,挥发性麻醉剂的心脏保护作用比缺血预处理或后处理出现得更早。尽管麻醉剂模拟缺血预处理或后处理的机制尚不清楚,但腺苷生成和信号传导是缺血预处理或后处理中最常见的触发因素。事实上,腺苷信号传导已被认为与异氟烷介导的心脏保护作用有关。腺苷通过四种受体发挥作用,分别命名为A1、A2a、A2b和A3。虽然每种受体亚型的作用仍存在争议,但心脏保护作用与所有亚型均有关联。许多争议源于大量的受体激动剂和拮抗剂,它们实际上能够与多种受体亚型相互作用。最近,更具特异性的受体激动剂和新的基因动物模型已出现,为新的发现铺平了道路。因此,腺苷A2b受体被证明是腺苷受体中唯一一种在小鼠和人类中其心脏表达均由缺血诱导且其功能与缺血预处理或后处理有关的受体。在本综述中,我们将重点关注麻醉剂心脏保护作用背景下的腺苷信号传导,并突出新的发现,这些发现可能会带来使用麻醉预处理治疗心肌缺血的新治疗理念。